News Letter Hamlet Biopharma 260724.2
Time Business News and USA Wire both highlight Hamlet Biopharma’s EMA approval for the phase III study of neoaduvant therapy for early bladder cancer and the collaboration with the University of Iowa and potential for advanced bladder cancer therapy.
The digital business magazines Time Business News and USA Wire have both highlighted Hamlet BioPharma’s collaboration with the University of Iowa regarding the development of Alpha1H treatment for patients with severe bladder cancer. The article outlines the advanced scientific and clinical background, the importance of the collaboration and its significance for Hamlet BioPharma.
Among other observations, the magazines describes Alpha1H as a promising treatment candidate for patients who do not respond to BCG therapy; a patient population for whom treatment options remain limited.
Both magazines also mention the EMA approval of the the Phase III study and the recent publication in the Journal of Infectius Diseases describing a novel drug candidate used successfully to treat bacterial infections in experimental models.
The attention strengthens Hamlet BioPharmas visibility in global markets.
Link to the articles: https://timebusinessnews.com/hamlet-biopharma-alpha1h-bladder-cancer-clinical-trial/
https://usawire.com/hamlet-biopharma-clinical-trial-expansion-us-eu-approval/
For further information, please contact
Catharina Svanborg, Chairman of the Board, Hamlet BioPharma AB, +46 709 42 65 49
catharina.svanborg@hamletpharma.com
Jakob Testad, CEO, Hamlet BioPharma AB, +46 708 48 42 10